Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.

Investigational new drugs - 1 Oct 2012

Sutherland Hamish S, Hwang In Young, Marshall Elaine S, Lindsay Brent S, Denny William A, Gilchrist Catherine, Joseph Wayne R, Greenhalgh Debra, Richardson Emma, Kestell Philip, Ding Angela, Baguley Bruce C

Abstract excerpt

PURPOSE: The human tumour suppressor protein p53 is mutated in nearly half of human tumours and most mutant proteins have single amino acid changes. Several drugs including the quinazoline derivative 1 (CP-31398) have been reported to restore p53 activity in mutant cells. The side chain of 1 contains a styryl linkage that compromises its stability and we wished to explore the activity of analogues containing more...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to DNA-Binding Proteins

Share to DNA Topoisomerases, Type II

Share to Mutant Proteins

Share to Quinazolines

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 21912889
DOI: 10.1007/s10637-011-9744-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic reactivation of mutant p53 protein by quinazoline derivatives.PMID 21912889Read ↗

The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce ApoptosisSemantic proximity Read ↗

Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function.Semantic proximity Read ↗

Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 BindingSemantic proximity Read ↗

A new family of small molecules to probe the reactivation of mutant p53.Semantic proximity Read ↗

Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cellsSemantic proximity Read ↗

Rescue of mutant p53 transcription function by ellipticine.Semantic proximity Read ↗

Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.Semantic proximity Read ↗

Design, Synthesis and In Vitro Activity of Anticancer Styrylquinolines. The p53 Independent Mechanism of Action.Semantic proximity Read ↗

An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cellsSemantic proximity Read ↗

Biological and Teratogenic Evaluations of Nitrogen Heterocycles for Anticancer TherapySemantic proximity Read ↗

The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways.Semantic proximity Read ↗

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.